Micafungin Hikma (Micafungin)

Micafungin inhibits the fungal enzyme β‑(1,3)‑D‑glucan synthase, which is required for synthesizing β‑(1,3)‑D‑glucan, an essential component of the fungal cell wall. Disruption of cell‑wall formation leads to osmotic instability and fungal cell death, while human cells are largely unaffected.

The prescribed dose of Micafungin Hikma is determined by the treating physician based on the specific infection, patient weight, renal and hepatic function, and clinical guidelines. Typical adult dosing ranges from 50 mg to 150 mg once daily, but exact regimens must be individualized by a qualified prescriber.

Micafungin’s pregnancy category is not definitively established. It should be used during pregnancy or lactation only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To order Micafungin Hikma, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles inhibit ergosterol synthesis and polyenes bind directly to ergosterol. Echinocandins, including micafungin, have a favorable safety profile and are effective against many Candida species, including those resistant to azoles, but they are administered intravenously rather than orally.

Micafungin Hikma should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the solution. Before use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required for infusion preparation.

Micafungin Hikma is administered by intravenous infusion. The recommended infusion time is typically 1 hour, but the exact rate should follow the prescribing information. The drug is supplied as a sterile solution for single‑use vials, and infusion sets should be compatible with the product to avoid drug adsorption.

Serious adverse events include severe hepatic dysfunction, anaphylactic reactions, Stevens‑Johnson syndrome or toxic epidermal necrolysis, acute renal failure, and profound hypotension during infusion. Patients should be monitored for signs of liver injury, allergic reactions, and hemodynamic changes, and therapy should be discontinued promptly if any of these occur.

Micafungin Hikma is contraindicated in patients with a known hypersensitivity to micafungin or any component of the formulation. Caution is advised in individuals with pre‑existing severe liver disease, uncontrolled renal impairment, or those receiving concomitant drugs that may cause dangerous interactions without appropriate monitoring.